JasonBierenbaumMD

PubMed

• 1 citations
  Patient, family caregiver, and economic outcomes of an integrated screening and novel stepped collaborative care intervention in the oncology setting in the USA (CARES...
  Jennifer L Steel, Charles J George, Lauren Terhorst, Jonathan G Yabes, Vincent Reyes
  Lancet. 2024-04-06
• 1 citations
  "A Tale of 2 Demons"-Concomitant Presence of Hepatocellular Carcinoma and Primary Neuroendocrine Tumor of Liver: A Case Report and Review of Literatures.
  Razwana Khanam, Pranali Santhoshini Pachika, Payam Arya, Jason Bierenbaum, Kevin Kane
  Journal of Investigative Medicine High Impact Case Reports. 2021-09-02
• 11 citations
  Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience
  Dan P. Zandberg, Franklin Hendrick, Emily J. Vannorsdall, Jason Bierenbaum, Michael L. Tidwell
  Leukemia & Lymphoma. 2013-02-01

Journal Articles

• Tertiary center referral patterns for patients with myelodysplastic syndrome are indicative of age and race disparities: a single-institution experience.  
  Zandberg DP, Hendrick F, Vannorsdall E, Bierenbaum J, Tidwell ML, Ning Y, Zhao XF, Davidoff AJ, Baer MR, Leuk Lymphoma, 2/1/2013
• Racial differences in presentation, referral and treatment patterns and survival in adult patients with acute myeloid leukemia: a single-institution experience.  
  Bierenbaum J, Davidoff AJ, Ning Y, Tidwell ML, Gojo I, Baer MR, Leuk Res, 2/1/2012
• Patient and physician characteristics associated with erythropoiesis-stimulating agent use in patients with myelodysplastic syndromes.  
  Davidoff AJ, Weiss Smith S, Baer MR, Ke X, Bierenbaum JM, Hendrick F, McNally DL, Gore SD, Haematologica, 1/1/2012
• Littoral cell angioma: A correctable cause of progressive pancytopenia in a patient with myelodysplastic syndrome.  
  Bierenbaum J, Alapat DV, Godinez C, Park AE, Zhao XF, Baer MR, Leuk Res, 10/22/2009
• Join now to see all

Abstracts/Posters

• The broad use of erythropoietic stimulating agents (ESA) for myelodysplastic syndromes (MDS) in the U.S. is not consistent with guidelines.
  A.J. Davidoff, M.R. Baer, S.R. Weiss Smith, X. Ke, J. Bierenbaum, F. Hendrick, D. McNally, S.D. Gore, 11th Annual International Symposium on Myelodysplastic Syndromes, Edinburgh, UK., 5/19/2011
• Race and Overall Survival in Acute Myeloid Leukemia.
  J Bierenbaum, Y Ning, M Tidwell, I Gojo, MR Baer, American Society of Clinical Oncology Annual Meeting, Chicago, IL., 1/1/2010
• Access to Care, Race and Education Are Key Determinants of Erythropoietin Stimulating Agent (ESA) Use In Myelodysplastic Syndromes (MDS).
  A Davidoff, S Smith, MR Baer, X Ke, J Bierenbaum, F Hendrick, D McNally, S Gore, American Society of Hematology Annual Meeting, Orlando, FL., 1/1/2010
• Tertiary Center Referral Patterns for Myelodysplastic Syndrome (MDS) Patients Are Suggestive of Age and Race Disparities.
  D Zandberg, J Bierenbaum, I Gojo, M Tidwell, Y Ning, X Zhao, A Davidoff, MR Baer, M.D, American Society of Hematology Annual Meeting, Orlando, FL., 1/1/2010
• Black Patients with Acute Myeloid Leukemia (AML) Are Younger and More Commonly Female, but Have a Higher Incidence of Complex Karyotypes When Compared to Whites.
  J Bierenbaum, Y Ning, A Hoffman, I Gojo, MR Baer, American Society of Hematology Annual Meeting, New Orleans, LA., 1/1/2009
• Cytokine Polymorphisms and Liver Transplant Outcomes.
  J Bierenbaum et al., World Congress of Gastroenterology, Montreal, Canada., 1/1/2006
• Join now to see all

Lectures

• Racial Disparities in Cancer: More than a Black and White Issue. 
  Hematology and Oncology Grand Rounds, University of Maryland School of Medicine. - 3/14/2011